Authors
Morgoshiia T.Sh., Kohanenko N.Yu., Ter-Ovanesov M.D., Syroezhin N.A.
St. Petersburg State Pediatric Medical University, St. Petersburg
Abstract
In the second part of the work, technological advances in endoscopic surgery are analyzed, which radically changed the treatment of dysplastic and early oncological diseases from aggressive to organ-preserving endoscopic treatment. A multimodal approach to treatment is shown, combining endoscopic resection of visible and/or protruding lesions with ablative methods for early forms of mucosal lesions in Barrett’s esophagus, followed by long-term follow-up, which improves the results of treatment of this nosological form. Safe and effective endoscopic treatment can be both tissue extraction, as with endoscopic resection of the mucous membrane with endoscopic submucous dissection, and tissue ablation, as with photodynamic therapy, radiofrequency stimulation and cryotherapy. It is shown that today the treatment of patients with Barrett’s esophagus consists of two main points: 1. Elimination of signs and manifestations of GERD; 2. Treatment of high-grade dysplasia and reduction of the risk of esophageal adenocarcinoma. It is noted that joint decision-making between the patient and the doctor is important when considering the treatment of dysplasia and Barrett’s esophagus.
Keywords: Barrett’s esophagus, gastroesophageal reflux disease, esophageal adenocarcinoma, endoscopy, dysplasia treatment, surgical treatment.
References
48. Williamson JML, Almond LM, Shepherd NA, Barr H. Current management of Barrett’s oesophagus. Br J Hosp Med (Lond). 2012; 73: 271-277.
49. Brown J, Alsop B, Gupta N, Buckles DC, Olyaee MS, Vennalaganti P, et al. Effectiveness of focal vs. balloon radiofrequency ablation devices in the treatment of Barrett’s esophagus. United European Gastroenterology J. 2015; 4(2): 236-241.
50. Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014; 39(9): 984-91.
51. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014; 63(8): 1229-37.
52. Kuipers EJ, Lundell L, Klinkenberg-Knoll EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fun-doplication. N Engl J Med. 1996; 334: 1018-1022.
53. McEntee GP, Stuart RC, Byrne PJ, et al. An evaluation of surgical and medical treatment of Barrett’s esophagus. Gullet. 1991; 1: 169-172.
54. Haidry R, Dunn J, Butt M, Burnell MG, Gupta A, Green S, et al. Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett’s Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013; 145(1): 87-95.
55. Clermont M, Falk G. Clinical Guidelines Update on the Diagnosis and Management of Barrett’s Esophagus. Dig. Dis. Sci. 2018; 63(8): 2122-2128.
56. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease—evaluation of primary repair in 100 consecutive patients. Ann Surg. 1986; 204: 9-20.
57. Ortiz A, Dehard M, Parrilla P, et al: Conservative treatment versus antireflux surgery in Barrett’s esophagus: Long-term results of a prospective study. Br J Surg. 1996; 83: 276-278.
58. Ye W, Chow WH, Lasergren Yin L, Nyrcn O. Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001; 121: 1286-1293.
59. McDonald ML, Trastek VF, Alien MS, et al Barrett’s esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg. 1996; 111: 1135-1140.
60. Spechler SJ. Barrett’s Esophagus. The New England Journal of Medicine. 2002; 346(11): 836-842.
61. Morgoshiya TSH. Sravnitel’naya ocenka hirurgicheskih vmeshatel’stv pri rake distal’nogo otdela zheludka. Vestnik hirurgii. 2006; 165; 2: 20-22. (In Russ).
62. Pech O, Behrens A, May A. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008; 57: 1200-1206.
63. Pouw RE, Wirths K, Eisendrath P. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010; 8: 23-29.
64. Manner H, Rabenstein T, Pech O. Ablation of remaining Barrett’s epithelium after endoscopic resection: a randomized long-term follow-up study on argon plasma coagulation versus surveillance (APE study). Endoscopy 2014; 46: 6-12.
65. Davydov MI, Ter-Ovanesov MD, Stilidi IS, Dyhno AYU, Poddubnyj BK, Kuvshinov YUP. Pishchevod Barretta: ot teoreticheskih osnov k prakticheskim rekomendaciyam. Prakticheskaya onkologiya. 2003; 4(2): 109-119. (In Russ).
66. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349: 2241-2252.
67. Pennathur A, Luketich JD. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg. 2014; 85: 751-756.
68. Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009; 87:1048-1054. Discussion: 1054-1055.
69. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002; 346:1128-1137.
70. Low DE, Kuppusamy MK, Alderson D et al. Benchmarking Complcations associated with esopagectomy. Ann Surg. 2019: 269: 291-296.
71. Markar S, Gronnier C et al. Patterns of postoperative mortality after esophageal cancer resection according to center volume: results from a large European Multicenter Study. Ann Surg Oncol. 2015; 22: 2615-2623.
72. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg. 2003; 238: 486-494. Discussion: 494-495.
73. Luketich JD, Pennathur A, Catalano PJ, et al. Results of a phase II multicenter study of MIE (Eastern Cooperative Oncology Group Study E2202). J Clin Oncol. 2012; 27.
74. Nafteux Ph, Depypere L, Veer H, Coosemans W. Lerut T. Principles of esophageal cancer surgery, including surgical approaches and optimal node dissection (2- vs 3-field). Annals of Cardiothoracic Surgery. 2017; 6: 152-158.
75. Maas KW, Cuesta MA, van Brge Henegouwen et al. Quality of life and late complications after minimally invasive compared to open esophagectomy: results of a randomized trial. World Journ Surg. 2015; 39: 1986-1993.
76. Low DE, Allum W, De Manzoni G, et al. Guidelines for perioperative cara in esophagectomy: Enhanced recovery after surgery (ERAS) Society recommendations. World J Surg. 2019; 43: 299-330.
77. Klevebro F, Boshier PR, Low DE. Application of standardized hemodynamic protocols within enhanced recovery after surgery programs to improve outcomes associated with anastomotic leak and conduit necrosis in patients undergoing esophagectomy. Journal of Thoracic Disease 2019; 11: 692-701.
